ABSTRACT Background: The inefficiency of HIV breast-milk transmission may be caused by the presence of immunologically active factors, including human milk oligosaccharides (HMOs). Objective: We investigated whether HMO concentrations are associated with a reduced risk of postnatal HIV transmission. Design: A nested case-control study was conducted within a larger cohort study of HIV-infected women and their infants followed from birth to 24 mo in Lusaka, Zambia. Breast-milk samples collected at 1 mo from 81 HIV-infected women who transmitted via breastfeeding, a random sample of 86 HIV-infected women who did not transmit despite breastfeeding, and 36 uninfected breastfeeding women were selected. Total and specific HMO concentrations were measured by HPLC and compared between groups with adjustment for confounders by using logistic regression. Results: HIV-infected women with total HMOs above the median (1.87 g/L) were less likely to transmit via breastfeeding (OR: 0.45; 95% CI: 0.21, 0.97; P = 0.04) after adjustment for CD4 count and breast-milk HIV RNA concentrations; a trend toward higher concentrations of lacto-N-neotetraose being associated with reduced transmission (OR: 0.49; 95% CI: 0.23, 1.04; P = 0.06) was also observed. The proportion of 3#-sialyllactose (3#-SL) per total HMOs was higher among transmitting than among nontransmitting women (P = 0.003) and correlated with higher plasma and breast-milk HIV RNA and lower CD4 counts. Neither Secretor nor Lewis status distinguished between transmitting and nontransmitting women. Conclusions: Higher concentrations of non-3#-SL HMOs were associated with protection against postnatal HIV transmission independent of other known risk factors. Further study of these novel, potentially anti-HIV components of breast milk is warranted. This trial was registered at clinicaltrials.gov as NCT00310726.
INTRODUCTION
HIV-1 can be transmitted from mother to child throughout the period of breastfeeding. However, the vast majority of breastfed infants do not acquire HIV-1 despite continuous exposure to the virus within their mothers' milk over many months. In the absence of antiretroviral drugs, w10-15% of infants will acquire infection from their HIV-infected mother via breastfeeding, depending on the duration of exposure (1) . The plethora of immunologically active milk components (2) may minimize the risk of transmission despite this intensive viral exposure.
We investigated the potential role of human milk oligosaccharides (HMOs) 4 in reducing the risk of postnatal HIV transmission via breastfeeding. These complex oligosaccharides are the third most abundant component of breast milk yet are not digestible and reach the mucosal surfaces of the infant's gastrointestinal tract at high concentrations (3) (4) (5) . HMOs act as prebiotics, which serve as metabolic substrate to promote the growth of desired bacterial communities in the infant's intestine (6, 7) . In addition, HMOs structurally resemble the glycans on epithelial cell surfaces and can serve as soluble decoy receptors that inhibit pathogen adhesion (3) (4) (5) 8) . HMOs can also directly affect intestinal epithelial cell maturation and integrity (9, 10) . Furthermore, HMOs have antiinflammatory activity in vitro and in animal models and have been shown to modulate immune cell responses through interactions with a wide variety of immune receptors, including Toll-like receptors, selectins, or dendritic cell-specific C-type lectins (11) (12) (13) (14) (15) (16) (17) (18) .
Many mechanisms by which HMOs may interfere with HIV infection have been postulated, but the strongest evidence comes from in vitro data, which suggest that HMOs interfere with the binding of HIV to dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-a C-type lectin on human dendritic cells (DCs) (19) (20) (21) . HIV binds to DC-SIGN, which carries the virus across the mucosal barrier (22) (23) (24) . DC-SIGN, however, not only binds HIV but has strong affinity to Lewis blood group antigens (25) , which are part of HMOs in the milk of some, but not all, women (3, 26, 27) .
More than 100 structurally distinct HMOs have been identified (3, 28) , but not every woman synthesizes and secretes each and every HMO. HMO composition depends highly on the woman's Secretor and Lewis blood group status (26, 29, 30) . We hypothesized that these interindividual differences in HMO amount and composition are associated with postnatal HIV transmission via breastfeeding. We tested this hypothesis by analyzing HMO amount and composition in breast-milk samples collected as part of a larger study of HIV-infected women and their infants followed from birth to 24 mo in Lusaka, Zambia (31) . Most of the cohort was recruited and followed before antiretroviral therapy (ART) became available and only single-dose nevirapine was used for the prevention of mother-to-child HIV transmission. Because it has been clearly established that maternal ART or extended infant prophylaxis substantially reduces postnatal transmission (32, 33) , our samples provide a unique opportunity to study associations between milk components and transmission in vivo undisturbed by ART and with a large number of infections to yield statistically informative comparisons.
SUBJECTS AND METHODS

Study design
A nested case-control study was conducted within the context of a randomized trial to test the safety and efficacy of abrupt cessation of breastfeeding at 4 mo on postnatal HIV transmission and child mortality. The trial was described in detail elsewhere (31) . In brief, 958 HIV-infected women, recruited during pregnancy at 2 antenatal care clinics in Lusaka, Zambia, between May 2001 and September 2004, were followed to delivery and through 24 mo postpartum with their infants. Women were given singledose nevirapine as prophylaxis to prevent transmission to the child. ART became available in the public sector only toward the end of the enrollment period. All women provided written informed consent for their participation, and all the investigators' Institutional Review Boards approved the study.
Only women who intended to breastfeed were enrolled, and all were counseled to breastfeed to $4 mo. Half of the women were randomly assigned to stop all breastfeeding at 4 mo and the other half to continue breastfeeding for a duration of their own choice. Heel-stick blood samples were collected from all infants at birth, monthly to 6 mo, and every 3 mo to 24 mo of age. DNA was extracted from each infant's blood sample and tested for HIV by real-time polymerase chain reaction. All positive test results were confirmed by testing $2 samples. All negative test results were confirmed to be adequate by the amplification of betaglobin. Maternal blood was collected at enrollment during pregnancy and tested for CD4 and CD8 cell counts (FACSCount system, BD Immunocytometry Systems), hemoglobin (Hemocue system), and plasma viral load (Roche Amplicor 1.5). Social and clinical data were collected at enrollment during pregnancy, at the time of delivery, and at each follow-up visit over the postnatal period.
Selection of cases and controls
Cases were defined as HIV-infected women who transmitted HIV to their infants via breastfeeding. HIV infection was inferred to have occurred during breastfeeding if infants had a first positive polymerase chain reaction test after 42 d of age with an earlier negative result. Ninety-three women met the case definition, giving a postnatal transmission rate (by Kaplan-Meier methods) of 12.7% by 24 mo. Of these, 87 attended the 1-mo visit and 81 had breast-milk samples available for testing. As nontransmitting controls, we randomly selected from among HIVinfected mothers who did not transmit despite breastfeeding, a sample of 96 women who breastfed .42 d using incidencedensity sampling (31) . Of these, 92 attended the 1-mo visit, and 86 had breast-milk samples available for testing. In addition, we selected all 36 HIV-uninfected women who had been recruited and followed as part of the same protocol at the same site but counseled to breastfeed for a duration of their own choice. We considered it important to select a single time point to test as declines in immunologically active components of milk, including HMOs, were described previously (27, (34) (35) (36) . One-month samples were selected for testing because these samples would be before postnatal HIV acquisition for all infants and are from a period when lactation is fully established for most infants.
Breast-milk processing and viral load measurement
Breast milk was manually expressed from each breast separately into clean sterile collection cups and transported to a central laboratory in Lusaka, where samples were stored at 4 8 C and processed within 4 h. Breast-milk samples were centrifuged, and the supernatant fluid was separated from the cell pellets. Cell pellets were removed and stored separately. Lipid and aqueous fractions of milk were mixed, portioned into aliquots, and then stored at 270 8 C. Samples were shipped on dry ice to the United States for further testing. Copies of HIV-1 RNA per milliliter of breast milk (viral load) were measured with the Roche Amplicor Ultrasensitive HIV-1 1.5 kit (Roche Molecular Systems Inc) with a lower detection limit of 50 copies/mL. The assay has been validated for quantitation of HIV-1 RNA in breast milk (37) . Because RNA quantity was nonnormally distributed, log-transformed data were used for analyses. For samples below the detection limit of the assay, a value of 49 copies/mL was imputed.
HMO measurement
HMOs were analyzed as previously described (38, 39) . Briefly, raffinose was added to 40 mL milk to serve as an internal standard through sample processing and analysis. Lipids and proteins were removed from the samples by centrifugation and chloroform-methanol extraction. Lactose was removed by overnight incubation on lactase-immobilized beads (Invitrogen) at 37 8 C. Residual peptides and salt were removed over Sep-Pak C 18 cartridges followed by porous graphitized carbon cartridges. The reducing end of the dried oligosaccharides was labeled with the fluorescent tag 2-aminobenzamide (2AB) for 2 h at 65 8 C (19). Free 2AB label was separated from the 2AB-labeled oligosaccharides by using silica gel cartridges. The 2AB-labeled oligosaccharides were analyzed by HPLC on an amide-80 column (4.6 mm inner diameter 3 25 cm, 5 mm; Tosoh Bioscience) with a 50-mmol/L ammonium formate-acetonitrile buffer system. Separation was performed at 25 8 C and monitored with a fluorescence detector at 360 nm excitation and 425 nm emission. Peak annotation was based on standard retention times and mass spectrometric analysis on a Thermo LCQ Duo Ion trap mass spectrometer equipped with a Nano-ESI-source.
The total concentration of HMOs was calculated as the sum of the most common oligosaccharides, including 2#-fucosyllactose (2#-FL), 3- 
Statistical methods
The distributions of total HMOs and specific HMOs and proportion of total HMO attributable to each specific type were compared between the groups on a continuous scale and were also categorized as either above or below the median concentration of the HMOs in the nontransmitting group. Student's t and nonparametric Wilcoxon's tests were used for continuous variables, and Pearson's chi-square statistics and Fisher's exact test were used for categorical variables. A Bonferroni correction was applied to adjust for multiple comparisons. Logistic regression was conducted to examine the relations between each HMO and transmission. Unadjusted and adjusted ORs were reported with 95% CIs. Maternal health indicators, including CD4 cell count, hemoglobin concentration, plasma viral load, breast-milk RNA viral load at 1 mo, and clinical stage were investigated as potential confounders. Women were defined as symptomatic if they experienced weight loss, .30 d of diarrhea, or fever or cough in the previous 6 mo or had a history of thrush or tuberculosis. Associations between HMOs and maternal CD4 cell count, plasma viral load, and breast-milk RNA viral load at 1 mo were described by using Spearman's correlation coefficients. Kaplan-Meier methods were used to calculate the duration of breastfeeding. All statistical analyses were performed by using SAS (version 9.2).
RESULTS
Cohort characteristics
Baseline characteristics of the 81 HIV-transmitting, 86 nontransmitting, and 36 uninfected control mother-child pairs are shown in Table 1 . Women who transmitted via breastfeeding had significantly lower CD4 cell counts and a higher plasma viral load than did the nontransmitting mothers. More HIV-uninfected mothers were aged ,20 y and had a higher hemoglobin concentration than did nontransmitting mothers.
Quantitation of human milk oligosaccharides
Median concentrations of total HMO in breast milk were 1.60, 1.87, and 1.64 g/L among transmitting, nontransmitting, and uninfected control mothers, respectively ( Table 2) . On a continuous scale, the distributions did not differ significantly between the groups. LNT, 2#-FL, and LNFP II+III were the most abundant HMOs, whereas 3-FL had the lowest concentration of the 3 groups. HIVinfected mothers had higher concentrations of 3#-SL (P , 0.01) and LNnT (P = 0.06) than did uninfected controls ( Table 2) . Concentrations of the other oligosaccharides did not differ significantly between the groups. If only the non-3#-SL HMO concentration was considered, the median concentrations were 1.48 and 1.76 among transmitting and nontransmitting mothers, respectively (P = 0.04).
The proportion of 3#-SL was significantly higher in HIVtransmitting mothers than in nontransmitting mothers (8.6% compared with 6.6%; P = 0.003), but the proportions of all other oligosaccharides were similar between the groups ( Table 2 ). The association between 3#-SL and transmission remained significant after Bonferroni adjustment (P = 0.02).
We also examined associations between the total HMO concentration and the proportion of each oligosaccharide per total HMO (Figure 2) . The proportion of each oligosaccharide per total HMO was significantly correlated with the total HMO concentration, except for LNT. The lower concentration of total HMO was strongly associated with a higher percentage of 3#-SL (Spearman's correlation coefficient = 20.50, P , 0.001). Similarly, a lower concentration of total HMO was significantly associated with a higher proportion of 3-FL and LNnT but with lower proportions of 2#-FL and LNFP I.
Maternal health and oligosaccharides
Associations between maternal health factors and oligosaccharides were investigated in HIV-infected women considering 3 Mean 6 SD (all such values). 4 Calculated by Kaplan-Meier methods and compared between the groups by using the log-rank test.
oligosaccharides as either absolute concentration or proportion per total HMO ( Figure 3 ). Higher proportions of 3#-SL were significantly associated with a lower CD4 cell count (Spearman's r = 20.20, P = 0.01), a higher plasma viral load (Spearman's r = 0.13, P = 0.09), and a higher breast-milk HIV RNA viral load (Spearman's r = 0.20, P = 0.01). The total HMO concentration and all other oligosaccharides were not associated with any of these indicators of more advanced maternal disease.
Postpartum HIV transmission and oligosaccharides
On a continuous scale, the total HMO concentration was not significantly associated with a reduced risk of postpartum HIV transmission, although a trend was apparent (adjusted OR for each log 10 increase in total HMO concentration: 0.31; 95% CI: 0.08, 1.21) ( Table 3) . When stratified by below and above the median, a higher total HMO concentration ($1.87 g/L) was significantly associated with a reduced risk of postpartum transmission after adjustment for the maternal CD4 cell count and breast-milk HIV RNA viral load at 1 mo (log scale) (adjusted OR: 0.45; 95% CI: 0.21, 0.97). If only non-3#-SL HMO was considered, the concentration above the median (1.76 g/L) was more strongly associated with a reduced transmission (adjusted OR: 0.38; 95% CI: 0.17, 0.82) than with the total HMO. The association between concentrations of each oligosaccharide and postpartum HIV transmission is described in Table 3 . Having Lewis-antigen or Secretor status was not associated with the risk of postpartum transmission. A nonsignificant trend toward higher concentrations of LNnT (mg/L) and a reduced risk of HIV was observed (adjusted OR: 0.49; 95% CI: 0.23, 1.04). All other oligosaccharides were not associated with postpartum transmission. When the proportion of each oligosaccharide in total HMO was considered, a higher proportion of 3#-SL was associated with a 2-fold increased risk of transmission (OR: 2.52; 95% CI: 1.33, 4.79). This remained significant after adjustment for the CD4 cell count and breast-milk HIV RNA viral load (adjusted OR: 2.21; 95% CI: 1.04, 4.73).
DISCUSSION
In the current study, we examined milk from .200 African women to investigate the role of HMO in HIV transmission. Epidemiologic and in vitro studies have shown that HMOs protect infants from a wide variety of pathogens (39) (40) (41) (42) (43) (44) . Our study indicates that these versatile substances may also play a role in protecting infants from HIV infection. Higher concentrations of total HMO, particularly non-3#-SL HMOs, including LNnT, were associated with protection against postnatal HIV transmission independent of other known risk factors such as CD4 count and breast-milk HIV RNA viral load. We also observed that the proportion of HMO due to 3#-SL was associated with increased transmission and markers of more advanced disease in the mother. These results indicate that it is the specific profile of HMOs that is important at determining whether or not HMOs play a role in mitigating HIV transmission via breastfeeding.
The type and amount of HMOs that infants receive from their mothers are variable and depend on maternal Secretor and Lewis blood group status (26, 29, 30) . Lewis X components in human milk bind DC-SIGN, compete with the HIV-1 envelope protein gp120 for binding to DC-SIGN, and inhibit HIV-1 transfer to CD4 + T lymphocytes (19) . Lewis X-containing bile salt-stimulated lipase was later identified as one of the inhibitory glycoproteins in human milk that bind to DC-SIGN and inhibit HIV-1 transfer to CD4 + T lymphocytes (20) . Whereas bile saltstimulated lipase concentrations in human milk range from 0.1 to 0.2 g/L (45), HMOs are much more abundant, with concentrations of 5 to 10 g/L. HMOs also carry Lewis blood group antigens and successfully compete with HIV-1-gp120 for binding to DC-SIGN in ELISA-and cell-based assays (21) . These data led us to hypothesize that Lewis-and Secretor-related interindividual differences in HMO amount and composition are associated with HIV transmission via breastfeeding. In the current study, however, the concentration of HMOs with Secretor-(2#-FL or LNFP I) or Lewis-active epitopes (LNFP II) did not correlate with HIV transmission risk. These results suggest that other HMOs contribute to the protection against postnatal HIV transmission and are independent of the mother's Secretor or Lewis blood group status. Our data suggest that protection may be mediated in part by concentrations of LNnT. This oligosaccharide is capable of shifting the composition of microbial communities in the intestine in vivo (46) , has antiinflammatory effects in vitro, and is produced by helminthes, where it has been found to be a potent suppressor of T helper 1 and inflammatory responses (12) . Other more complex HMOs that were not included in our analysis might also contribute to the protective effects. There are .100 structurally different HMOs, each of which probably has a distinct role as a receptor analog for pathogens and/or as immune modulators. Most intriguing are the unexpected results concerning 3#-SL. The percentage of 3#-SL was higher among transmitting than among nontransmitting mothers. Also, women with a higher percentage of 3#-SL were more likely to have higher plasma and breast-milk HIV RNA concentrations and lower CD4 counts. In contrast with the other HMOs in this analysis, 3#-SL is sialylated and appears to have proinflammatory properties, including T cell stimulation (15) and promotion of intestinal inflammation (47) . The correlation between a high percentage of 3#-SL in the mother's milk and high viral load in the mother's plasma and milk raises questions about causalities. Altered antibody glycosylation is well described in inflammatory states such as autoimmune diseases, pregnancy, and aging, and the respective cytokine milieu may play a role (48) . Therefore, it is plausible that the inflammatory signals associated with a high viral load may induce the synthesis of 3#-SL in the mammary gland. Indeed, altered cellular glycosylation has been described in HIV-infected cells (49) . Whether increased 3#-SL concentrations represent a host response to counteract HIV, or whether they directly or indirectly promote HIV infection, requires further investigation.
Whereas the current study focused on a selected subset of some of the most abundant HMOs, milk bioactive compounds other than HMOs may also decrease the risk of HIV transmission through breastfeeding. In fact, data from the same cohort showed various levels of protection associated with the concentration of breast milk defensins (50), various cytokines, and chemokines as well as several other factors (51, 52) . We did not, however, find associations between transmission risk and concentrations of breast-milk IgA HIV-specific antibodies or CCL28 (53, 54) . In addition, in vitro data suggest that sulfated glycolipids and glycosaminoglycans in breast milk may also contribute to an inhibition of HIV transmission (55) . It is possible that HMOs and other bioactive compounds in breast milk synergize to decrease HIV transmission.
Breastfed infants provide a unique human challenge model in which to investigate factors that modulate the risk of mucosal HIV transmission (56) . Whereas maternal ART or extended infant prophylaxis are known to prevent postnatal transmission (32, 33) , the samples analyzed in the current study were collected before ART became available (31) . Thus, this large and welldefined cohort provided a unique and powerful opportunity to study associations between HMO and HIV transmission in vivo. In the future, a better understanding of how individual HMOs facilitate or obstruct HIV transmission may guide the development of interventions to complement antiretroviral strategies and more effectively prevent transmission.
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